首页> 美国卫生研究院文献>British Journal of Cancer >A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

【2h】

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

机译：中枢性社会抗癌药物研究（CESAR）协作网络中的一项针对Polo样激酶抑制剂BI 2536在未经化疗的胰腺外分泌腺癌患者中进行的随机II期临床试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: BI 2536, a novel Polo-like kinase 1 inhibitor, was assessed in patients with unresectable advanced exocrine adenocarcinoma of the pancreas.

机译：背景：BI 2536，一种新型的Polo样激酶1抑制剂，在患有无法切除的胰腺晚期外分泌腺癌的患者中进行了评估。

著录项

期刊名称 British Journal of Cancer
作者
K Mross; C Dittrich; W E Aulitzky; D Strumberg; J Schutte; R M Schmid; S Hollerbach; M Merger; G Munzert; F Fleischer; M E Scheulen;
展开▼
作者单位

展开▼
年(卷),期 2012(107),2
年度 2012
页码 280–286
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
pancreatic cancer Plk1 inhibitor phase II BI 2536;

机译：胰腺癌;Plk1抑制剂;II期;BI 2536;

相似文献

外文文献
中文文献

1. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). [J] . Schoffski P, Blay JY, De Greve J, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2010,第12期

机译：polo样激酶1抑制剂BI 2536在晚期头颈癌，乳腺癌，卵巢癌，软组织肉瘤和黑色素瘤患者中的多中心平行II期试验。欧洲癌症研究与治疗组织（EORTC）核心研究所网络（NOCI）的第一个协议。
2. 1260 Multicenter parallel phase II trials of the polo-like kinase 1 inhibitor BI-2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organisation for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI) [J] . P.Sch?ffski, J.Y.Blay, J.DeGreve, European Journal of Cancer Supplements . 2009,第2期

机译：polo样激酶1抑制剂BI-2536在患有晚期头颈癌，乳腺癌，卵巢癌，软组织肉瘤和黑色素瘤的患者中进行的1260多中心平行II期试验。欧洲癌症研究与治疗组织（EORTC）核心研究所网络（NOCI）的第一个协议
3. BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR) [J] . R.-D. Hofheinz, C. Porta, G. Hartung, Investigational New Drugs . 2005,第4期

机译：BBR 3438，一种新型9-氮杂-蒽吡唑，用于晚期胃癌患者：中欧抗癌药物研究协会（CESAR）的II期研究组试验
4. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV [O] . S Steinbild, K Mross, A Frost, 2007

机译：索拉非尼在进行性激素难治性前列腺癌患者中的临床II期研究：CESAR中欧抗癌药物研究协会（EWIV）的研究
5. A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-na\uefve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network [O] . Mross, Klaus, Dittrich, Christian, Aulitzky, Walter E., 2012

机译：Polo样激酶抑制剂BI 2536在未接受化疗的胰腺外分泌腺癌的初治患者中的随机II期试验-中欧学会抗癌药物研究（CESAR）协作网络中的一项研究

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

摘要

著录项

相似文献

相关主题

期刊订阅